News Hims & Hers buys Zava to form European beachhead US telehealth company Hims & Hers has reached a deal to buy its UK counterpart Zava as part of a broader push into Europe.
News ASCO 25: Can GLP-1 drugs reduce cancer risk? A study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight.
News Novo makes fresh obesity play with $2.2bn Septerna deal A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.
News More data backs Zepbound over Wegovy for weight loss Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.
News Lilly hit as PBM drops Zepbound, but retains Wegovy Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.
